Identification of drug-drug interactions in vitro: A case study evaluating the effects of sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes

Toxicological Sciences

Volumn 154, Issue 1, 2016, Pages 174-182

  Millard, Daniel C ^a   Strock, Christopher J ^b   Carlson, Coby B ^c   Aoyama, Natsuyo ^c   Juhasz, Krisztina ^d,e   Goetze, Tom A ^d   Stoelzle Feix, Sonja ^d   Becker, Nadine ^d   Fertig, Niels ^d   January, Craig T ^f   Anson, Blake D ^b   Ross, James D ^a  

^a AXION BIOSYSTEMS   (United States)

^b CYPROTEX DISCOVERY LTD   (United Kingdom)

^c Cellular Dynamics International A FUJIFILM Company   (United States)

^d NANION TECHNOLOGIES GMBH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cardiac electrophysiology; Cardiomyocyte; Drug interactions; Safety; Stem cell

Indexed keywords

AMIODARONE; CALCIUM CHANNEL; DRUG METABOLITE; GS 331007; ION CHANNEL; MULTIDRUG RESISTANCE PROTEIN; POTASSIUM; SODIUM; SOFOSBUVIR; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATED PATCH CLAMP; CALCIUM CELL LEVEL; CALCIUM CURRENT; CARDIAC MUSCLE CELL; CASE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; ELECTRIC POTENTIAL; EXCITATION CONTRACTION COUPLING; FEASIBILITY STUDY; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL; MAXIMUM PLASMA CONCENTRATION; POTASSIUM TRANSPORT; SODIUM TRANSPORT; WAVEFORM; DRUG EFFECTS; DRUG INTERACTION;

AMIODARONE; DRUG INTERACTIONS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; SOFOSBUVIR;

EID: 85006289207     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfw153     Document Type: Article

References (38)

1. Anderson, J. R. and Nawarskas, J. J. (2001). Cardiovascular drugdrug interactions. Cardiol. Clin 19, 215-234, v.
2. Back, D. J. and Burger, D. M. (2015). Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned. Gastroenterology 149, 1315-1317.
3. Becker, N., Stoelzle, S., Göpel, S., Guinot, D., Mumm, P., Haarmann, C., Malan, D., Bohlen, H., Kossolov, E., Kettenhofen, R., et al. (2013). Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system. J. Pharmacol. Toxicol. Methods 68, 82-87.
4. Bers, D. M. (2002). Cardiac excitation-contraction coupling. Nature 415, 198-205.
5. Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31, 815-832.
6. Braam, S. R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., and Mummery, C. L. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 4, 107-116.
7. Bruegmann, T., Malan, D., Hesse, M., Beiert, T., Fuegemann, C.J., Fleischmann, B.K., and Sasse, P. (2010). Optogenetic control of heart muscle in vitro and in vivo. Nat. Methods 7, 897-900.
8. Brüggemann, A., Farre. C., Haarmann, C., Haythornthwaite, A., Kreir, M., Stoelzle, S., George, M., and Fertig, N. (2009). Planar patch clamp: advances in electrophysiology. Methods Mol. Biol., 491, 165-176.
9. Clements, M. and Thomas, N. (2014). High-throughput multiparameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol. Sci., 140, doi: 10.1093/toxsci/ kfu084.
10. DeWitt, C. R. and Waksman, J. C. (2004). Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol. Rev., 23, 223-238.
11. Doerr, L., Thomas, U., Guinot, D.R., Bot, C.T., Stoelzle-Feix, S., Beckler, M., George, M., and Fertig, N. (2015). New easy-to-use hybrid system for extracellular potential and impedance recordings. J. Lab. Autom. 20, 175-188.
12. Ten Eick, R. E., and Hoffman, B. F. (1969). Chronotropic effect of cardiac glycosides in cats, dogs, and rabbits. Circ. Res. 25, 365-378.
13. FDA (2015). FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. FDA Drug Saf. Commun.
14. Fenner, K. S., Troutman, M. D., Kempshall, S., Cook, J. A., Ware, J. A., Smith, D. A., and Lee, C. A. (2009). Drug-drug interactions mediated through p-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85, 173-181.
15. Fridericia, L. S. (1920). Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med. Scand. 53, 469-486.
16. Gilchrist, K.H., Lewis, G.F., Gay, E.A., Sellgren, K.L., and Grego, S. (2015). High-throughput cardiac safety evaluation and multiparameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. Toxicol. Appl. Pharmacol. 288(2):249-257.
17. Gilead Sciences Inc. (2013) Sovaldi (sofosbuvir) tablets, for oral use: US prescribing information.
18. Guo, L., Coyle, L., Abrams, R.M., Kemper, R., Chiao, E.T., and Kolaja, K.L. (2013). Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol. Sci. 136, 581-594.
19. Gurwitz, J.H., Field, T.S., Harrold, L.R., Rothschild, J., Debellis, K., Seger, A.C., Cadoret, C., Fish, L.S., Garber, L., Kelleher, M., et al. (2003). Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107-1116.
20. Hager, W.D., et al. (1979). Digoxin-quinidine interaction Pharmacokinetic evaluation. N. Engl. J. Med. 300, 1238-1241.
21. Hajjar, E.R., Cafiero, A.C., and Hanlon, J.T. (2007). Polypharmacy in elderly patients. Am. J. Geriatr. Pharmacother. 5, 345-351.
22. Harris, K., Aylott, M., Cui, Y., Louttit, J.B., McMahon, N.C., and Sridhar, A. (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 134, 412-426.
23. Jacobson, I.M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., and Schiff, E. (2013). Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1867-1877.
24. Katz, A.M. (1993). Cardiac ion channels. N. Engl. J. Med. 328, 1244-1251.
25. Keating, G. M. (2014). Sofosbuvir: A review of its use in patients with chronic hepatitis C. Drugs 74, 1127-1146
26. Köhler, G. I., Bode-Böger, S. M., Busse, R., Hoopmann, M., Welte, T., and Böger, R. H. (2000). Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int. J. Clin. Pharmacol. Ther. 38, 504-513.
27. Latini, R., Tognoni, G., and Kates, R.E. (1984). Clinical Pharmacokinetics of Amiodarone. Clin. Pharmacokinet. 9, 136-156.
28. Lawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., Symonds, W. T., McHutchison, J. G., and Membreno, F. E. (2014). Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 383, 515-523.
29. Lawitz, E. J., Rodriguez-Torres, M., Denning J., Mathias A., Mo, H., Gao, B., Cornpropst, M. T., Berrey, M. M., and Symonds, W. T. (2013). All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR). J. Viral Hepat. 20, 699-707.
30. Lorberbaum, T., Sampson, K. J., Woosleym, R. L., Kassm, R. S., and Tatonettimm N. P. (2016). An integrative data science pipeline to identify novel drug interactions that prolong the QT interval. Drug Saf. 39, 433-441.
31. Ma, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kamp, T. J., Kolaja, K. L., Swanson, B. J., and January, C. T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart. Circ. Physiol., 301, 2006-2017.
32. Nutescu, E., Chuatrisorn, I., and Hellenbart, E. (2011). Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J. Thromb. Thrombolysis 31, 326-343.
33. Obergrussberger, A., Haarmann, C., Rinke, I., Becker, N., Guinot, D., Brueggemann, A., Stoelzle-Feix, S., George, M., and Fertig, N. (2014). Automated patch clamp analysis of nACha7 and NaV 1.7 channels. Curr. Protoc. Pharmacol. 65, 11.13.1-11-13.48.
34. Postma, A. V., Denjoy, I., Kamblock, J., Alders, M., Lupoglazoff, J. M., Vaksmann, G., Dubosq-Bidot, L., Sebillon, P., and Mannens, M. M. (2005). Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J. Med. Genet. 42, 863-870.
35. Prueksaritanont, T., Chu, X., Gibson, C., Cui, D., Yee, K.L., Ballard, J., Cabalu, T., and Hochman, J. (2013). Drug-drug interaction studies: regulatory guidance and an industry perspective. Aaps J. 15, 629-645.
36. Renet, S., Chaumais, M. C., Antonini, T., Zhao, A., Thomas, L., Savoure, A., Samuel, D., Duclos-Vallée, J. C., and Algalarrondo, V. (2015). Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology.
37. Soriano, V., Labarga, P., Barreiro, P., Fernandez-Montero, J. V., de Mendoza, C., Esposito, I., Benítez-Gutiérrez, L., and Peña, J. M. (2015). Drug interactions with new hepatitis C oral drugs. Expert Opin. Drug Metab. Toxicol. 11, 333-341.
38. Straubhaar, B., Krähenbühl, S., and Schlienger, R. G. (2006). The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf. 29, 79-90.